The Prognostic Value of High-Sensitivity Cardiac Troponin in Stable Coronary Artery Disease: A Systematic Review and Meta-analysis
DOI:
https://doi.org/10.54361/LJMR.19.2.41Keywords:
high-sensitivity cardiac troponin, stable coronary artery disease, prognosis, meta-analysis, risk stratification, cardiovascular outcomesAbstract
Background: High-sensitivity cardiac troponin (hs-cTn) assays can detect myocardial injury at significantly lower concentrations than conventional assays. While the diagnostic and prognostic value of hs-cTn in acute coronary syndromes is well-established, its prognostic significance in stable coronary artery disease (CAD) remains less defined. This systematic review and meta-analysis aimed to evaluate the prognostic value of hs-cTn for adverse outcomes in patients with stable CAD. Matrial and Methods: We conducted a systematic search of PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science from inception to May 2025. Studies reporting the association between baseline hs-cTn levels and clinical outcomes in stable CAD patients were included. The primary outcomes were all-cause mortality and major adverse cardiovascular events (MACE). Random-effects meta-analysis was performed to calculate pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Results: Ten studies comprising 14,938 patients with stable CAD were included in the quantitative analysis. Elevated hs-cTn levels were significantly associated with increased risk of all-cause mortality (pooled HR: 1.50, 95% CI: 1.43-1.57, I² = 24.0%) and cardiovascular events (pooled HR: 1.44, 95% CI: 1.38-1.51, I² = 50.8%). The prognostic value remained consistent across different hs-cTn assays (T and I) and was independent of traditional risk factors, renal function, and left ventricular ejection fraction. A troponin ratio >0.24 (relative to the 99th percentile upper reference limit) identified over 50% of patients at risk for death and heart failure hospitalization. Conclusions: Elevated hs-cTn levels are independently associated with increased risk of mortality and cardiovascular events in patients with stable CAD. Incorporating hs-cTn measurement into risk stratification algorithms may improve prognostic assessment in this population. Future research should focus on establishing optimal cutoff values and determining whether hs-cTn-guided management strategies can improve outcomes.
Downloads
References
1. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021.
2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
3. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-1357.
4. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231-2264.
5. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54-61.
6. Giannitsis E, Katus HA. Cardiac troponin level elevations not related to acute coronary syndromes. Nat Rev Cardiol. 2013;10(11):623-634.
7. Willeit P, Welsh P, Evans JDW, et al. High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants. J Am Coll Cardiol. 2017;70(5):558-568.
8. Everett BM, Brooks MM, Vlachos HE, et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med. 2015;373(7):610-620.
9. Blankenberg S, Salomaa V, Makarova N, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37(30):2428-2437.
10. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361(26):2538-2547.
11. Aimo A, Januzzi JL Jr, Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. 2018;137(3):286-297.
12. Mair J, Lindahl B, Hammarsten O, et al. How is cardiac troponin released from injured myocardium? Eur Heart J Acute Cardiovasc Care. 2018;7(6):553-560.
13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
14. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta- analyses. BMJ. 2003;327(7414):557-560.
16. Strunz CM, Hueb W, Rezende PC, et al. High-Sensitivity Troponin I and Cardiovascular Events in Stable Coronary Artery Disease: Insights from a Longitudinal Outpatient Study. Int J Mol Sci. 2023;24(24):17286.
17. Aimo A, Januzzi JL Jr, Vergaro G, et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation. 2018;137(3):286-297.
18. Korosoglou G, Lehrke S, Mueller D, et al. Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart. 2011;97(10):823-831.
19. Eggers KM, Lind L, Venge P, Lindahl B. Factors influencing the 99th percentile of cardiac troponin I evaluated in community-dwelling individuals at 70 and 75 years of age. Clin Chem. 2013;59(7):1068-1073.
20. Seliger SL, Hong SN, Christenson RH, et al. High-Sensitive Cardiac Troponin T as an Early Biochemical Signature for Clinical and Subclinical Heart Failure: MESA (Multi- Ethnic Study of Atherosclerosis). Circulation. 2017;135(16):1494-1505.
21. Ndrepepa G, Braun S, Mehilli J, et al. Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. Am Heart J. 2011;161(1):68-75.
22. Chin CWL, Shah ASV, McAllister DA, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J. 2014;35(34):2312-2321.
23. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11): 987-1003.
24. Wilson PWF, D'Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695-703.e1.
25. White HD, Tonkin A, Simes J, et al. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). J Am Coll Cardiol. 2014;63(4): 345-354.
26. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ahmed Abdelraso, Rasha J Abraheem, Ahmed S Mikael, Mahmoud A. Aloriby, Mohamed K A Elkawafi , Tarik Ali Alghoj, Yousef M. A. Hasen, Hamza A Osman, Amani Ibrahim (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access Policy
Libyan journal of medical Research (LJMR).is an open journal, therefore there are no fees required for downloading any publication from the journal website by authors, readers, and institution.
The journal applies the license of CC BY (a Creative Commons Attribution 4.0 International license). This license allows authors to keep ownership f the copyright of their papers. But this license permits any user to download , print out, extract, reuse, archive, and distribute the article, so long as appropriate credit is given to the authors and the source of the work.
The license ensures that the article will be available as widely as possible and that the article can be included in any scientific archive.
Editorial Policy
The publication of an article in a peer reviewed journal is an essential model for Libyan journal of medical Research (LJMR). It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editorial, the peer reviewer and the publisher.
Any manuscript or substantial parts of it, submitted to the journal must not be under consideration by any other journal. In general, the manuscript should not have already been published in any journal or other citable form, although it may have been deposited on a preprint server. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights, or the rights of a third party.
Authorship Policy
The manuscript authorship should be limited to those who have made a significant contribution and intellectual input to the research submitted to the journal, including design, performance, interpretation of the reported study, and writing the manuscript. All those who have made significant contributions should be listed as co-authors.
Others who have participated in certain substantive aspects of the manuscript but without intellectual input should only be recognized in the acknowledgements section of the manuscript. Also, one of the authors should be selected as the corresponding author to communicate with the journal and approve the final version of the manuscript for publication in the LJMR.
Peer-review Policy
- All the manuscripts submitted to LJMR will be subjected to the double-blinded peer-review process;
- The manuscript will be reviewed by two suitable experts in the respective subject area.
- Reports of all the reviewers will be considered while deciding on acceptance/revision or rejection of a manuscript.
- Editor-In-Chief will make the final decision, based on the reviewer’s comments.
- Editor-In-Chief can ask one or more advisory board members for their suggestions upon a manuscript, before making the final decision.
- Associate editor and review editors provide administrative support to maintain the integrity of the peer-review process.
- In case, authors challenge the editor’s negative decision with suitable arguments, the manuscript can be sent to one more reviewer and the final decision will be made based upon his recommendations.
